NCT02936414View on ClinicalTrials.gov

Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients

NACompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

December 31, 2015

Conditions
Schizophrenia
Interventions
DRUG

Berberine

Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.

DRUG

Placebo

Accept placebo(300 mg/tid)+SGAs monotherapy.

Trial Locations (1)

300222

Tianjin Anding Hospital, Tianjin

All Listed Sponsors
lead

Tianjin Anding Hospital

OTHER

NCT02936414 - Berberine Effect on Cytokine, CRP, Metabolic Disturbance as an Adjunctive Therapy in Schizophrenia Patients | Biotech Hunter | Biotech Hunter